Holkova, B., Shafer, D., Yazbeck, V., Dave, S., Bose, P., Tombes, M. B., . . . Grant, S. (2020). Phase 1 Study of Belinostat (PXD-101) and Bortezomib (Velcade, PS-341) in Patients with Relapsed or Refractory Acute Leukemia and Myelodysplastic Syndrome. Leuk Lymphoma.
Citação norma ChicagoHolkova, Beata, et al. "Phase 1 Study of Belinostat (PXD-101) and Bortezomib (Velcade, PS-341) in Patients With Relapsed or Refractory Acute Leukemia and Myelodysplastic Syndrome." Leuk Lymphoma 2020.
Citação norma MLAHolkova, Beata, et al. "Phase 1 Study of Belinostat (PXD-101) and Bortezomib (Velcade, PS-341) in Patients With Relapsed or Refractory Acute Leukemia and Myelodysplastic Syndrome." Leuk Lymphoma 2020.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.